Share on StockTwits

Equities researchers at Leerink Swann initiated coverage on shares of Exelixis (NASDAQ:EXEL) in a research report issued on Tuesday, reports. The firm set a “market perform” rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Analysts at Maxim Group raised their price target on shares of Exelixis from $7.50 to $11.00 in a research note to investors on Tuesday, January 21st. They now have a “buy” rating on the stock. Separately, analysts at Piper Jaffray upgraded shares of Exelixis from a “neutral” rating to an “overweight” rating in a research note to investors on Monday, January 6th.

Exelixis (NASDAQ:EXEL) traded down 1.97% during mid-day trading on Tuesday, hitting $6.96. 8,394,743 shares of the company’s stock traded hands. Exelixis has a 52 week low of $4.32 and a 52 week high of $8.41. The stock’s 50-day moving average is $6.69 and its 200-day moving average is $5.63. The company’s market cap is $1.282 billion.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.01. The company had revenue of $5.50 million for the quarter, compared to the consensus estimate of $5.55 million. During the same quarter in the previous year, the company posted ($0.20) earnings per share. The company’s revenue for the quarter was down 58.6% on a year-over-year basis. Analysts expect that Exelixis will post $-1.32 EPS for the current fiscal year.

Exelixis, Inc (NASDAQ:EXEL) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.